Protocol Ledger

NCT05504083 · Phase II · COMPLETED

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Interventional Phase II clinical trial protocol NCT05504083 sponsored by InventisBio Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-28 Enrollment: 121 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05504083
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05504083
Protocol FieldVerified Registry Value
NCT IdentifierNCT05504083
Consolidated Lead SponsorInventisBio Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment121 participants (ACTUAL)
Registered Start Date2022-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI